New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT07141706
Summary
This is the first human study of an experimental drug called DB-1317 for people with advanced solid tumors that have stopped responding to standard treatments. Researchers will test increasing doses in about 233 participants to find the safest amount and see if the drug can shrink tumors. The study focuses on safety first, then will look at whether the drug shows promise against specific cancers like gastric, colorectal, and pancreatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AUS01-0
RECRUITINGRandwick, New South Wales, 2031, Australia
-
USA01
RECRUITINGFairfax, Virginia, 22031, United States
-
USA02-0
RECRUITINGHouston, Texas, 77030, United States
-
USA03-0
RECRUITINGSan Antonio, Texas, 78229, United States
-
USA04-0
RECRUITINGLos Angeles, California, 90025, United States
Conditions
Explore the condition pages connected to this study.